Literature DB >> 24900047

Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau Disease.

Jong-Ryool Oh1, Harshad Kulkarni2, Cecilia Carreras2, Georg Schalch2, Jung-Joon Min1, Richard P Baum2.   

Abstract

Von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome with a variety of benign and malignant tumors such as retinal and central nervous system hemangioblastomas, endolymphatic sac tumors, renal cysts and tumors, pancreatic cysts and tumors, pheochromocytomas, and epididymal cystadenomas. Cross-sectional modalities (computed tomography and magnetic resonance imaging) as well as ultrasound play a major role in the initial evaluation and follow-up of the various manifestations of VHL disease. Ga-68-labeled somatostatin receptor analogs already have a significant role in the diagnosis, staging, and therapy management of neuroendocrine neoplasms and neural crest tumors. Herein, we report a case presenting a variety of malignancies in VHL and showing the usefulness of Ga-68 somatostatin receptor PET/CT as a one-stop-shop imaging modality in the management of VHL disease.

Entities:  

Keywords:  Ga-68 DOTA-NOC PET/CT; Ga-68 DOTA-TATE PET/CT; Ga-68 DOTA-TOC PET/CT; Hemangioblastoma; Pheochromocytoma; von Hippel-Lindau disease

Year:  2012        PMID: 24900047      PMCID: PMC4042996          DOI: 10.1007/s13139-012-0133-0

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  15 in total

1.  Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison.

Authors:  Hani B Marcos; Steven K Libutti; H Richard Alexander; Irina A Lubensky; David L Bartlett; McClellan M Walther; W Marston Linehan; Gladys M Glenn; Peter L Choyke
Journal:  Radiology       Date:  2002-12       Impact factor: 11.105

Review 2.  Von Hippel-Lindau disease and endocrine tumour susceptibility.

Authors:  Emma R Woodward; Eamonn R Maher
Journal:  Endocr Relat Cancer       Date:  2006-06       Impact factor: 5.678

3.  [18F]FDG PET/CT in pancreatic neuroendocrine tumours associated with von Hippel Lindau Syndrome.

Authors:  John Kok; Michael Lin; Vincent Wong; Peter Campbell; Peter Lin
Journal:  Clin Endocrinol (Oxf)       Date:  2008-09-22       Impact factor: 3.478

Review 4.  Von Hippel-Lindau disease: strategies in early detection (renal-, adrenal-, pancreatic masses).

Authors:  F J Hes; M A Feldberg
Journal:  Eur Radiol       Date:  1999       Impact factor: 5.315

5.  Pancreatic manifestations of von Hippel-Lindau disease-effect of imaging on clinical management.

Authors:  Matthew S Davenport; Elaine M Caoili; Richard H Cohan; Carrie N Hoff; James H Ellis
Journal:  J Comput Assist Tomogr       Date:  2010-07       Impact factor: 1.826

6.  The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome.

Authors:  Priya Kaji; Jorge A Carrasquillo; W Marston Linehan; Clara C Chen; Graeme Eisenhofer; Peter A Pinto; Edwin W Lai; Karel Pacak
Journal:  Eur J Endocrinol       Date:  2007-04       Impact factor: 6.664

Review 7.  Imaging features of von Hippel-Lindau disease.

Authors:  Rebecca S Leung; Sona V Biswas; Mark Duncan; Sheila Rankin
Journal:  Radiographics       Date:  2008 Jan-Feb       Impact factor: 5.333

Review 8.  Von Hippel-Lindau disease: new strategies in early detection and treatment.

Authors:  N Karsdorp; A Elderson; D Wittebol-Post; R J Hené; J Vos; M A Feldberg; A P van Gils; J M Jansen-Schillhorn van Veen; T M Vroom; J W Höppener
Journal:  Am J Med       Date:  1994-08       Impact factor: 4.965

Review 9.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

10.  Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma.

Authors:  B R Seizinger; G A Rouleau; L J Ozelius; A H Lane; G E Farmer; J M Lamiell; J Haines; J W Yuen; D Collins; D Majoor-Krakauer
Journal:  Nature       Date:  1988-03-17       Impact factor: 49.962

View more
  7 in total

1.  Kidney Tumor in a von Hippel-Lindau (VHL) Patient With Intensely Increased Activity on 68Ga-DOTA-TATE PET/CT.

Authors:  Georgios Z Papadakis; Corina Millo; Samira M Sadowski; Ulas Bagci; Nicholas J Patronas
Journal:  Clin Nucl Med       Date:  2016-12       Impact factor: 7.794

Review 2.  Artificial Intelligence in Medical Imaging and its Impact on the Rare Disease Community: Threats, Challenges and Opportunities.

Authors:  Navid Hasani; Faraz Farhadi; Michael A Morris; Moozhan Nikpanah; Arman Rhamim; Yanji Xu; Anne Pariser; Michael T Collins; Ronald M Summers; Elizabeth Jones; Eliot Siegel; Babak Saboury
Journal:  PET Clin       Date:  2022-01

3.  Epididymal Cystadenomas in von Hippel-Lindau Disease Showing Increased Activity on 68Ga DOTATATE PET/CT.

Authors:  Georgios Z Papadakis; Corina Millo; Samira M Sadowski; Ulas Bagci; Nicholas J Patronas
Journal:  Clin Nucl Med       Date:  2016-10       Impact factor: 7.794

4.  Endolymphatic Sac Tumor Showing Increased Activity on 68Ga DOTATATE PET/CT.

Authors:  Georgios Z Papadakis; Corina Millo; Samira M Sadowski; Ulas Bagci; Nicholas J Patronas
Journal:  Clin Nucl Med       Date:  2016-10       Impact factor: 7.794

5.  Splenosis Mimicking Relapse of a Neuroendocrine Tumor at Gallium-68-DOTATOC PET/CT.

Authors:  Giorgio Treglia; Luca Giovanella; Barbara Muoio; Carmelo Caldarella
Journal:  Nucl Med Mol Imaging       Date:  2013-11-26

6.  Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target.

Authors:  Saman Sizdahkhani; Michael J Feldman; Martin G Piazza; Alexander Ksendzovsky; Nancy A Edwards; Abhik Ray-Chaudhury; Dragan Maric; Marsha J Merrill; Karel Pacak; Zhengping Zhuang; Prashant Chittiboina
Journal:  Sci Rep       Date:  2017-01-17       Impact factor: 4.379

Review 7.  Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease.

Authors:  Xavier M Keutgen; Pascal Hammel; Peter L Choyke; Steven K Libutti; Eric Jonasch; Electron Kebebew
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.